About MorphoSys
MorphoSys is a Healthcare company based in Planegg (Germany) founded in 1992 by Andreas Pluckthun, and was acquired by Novartis in February 2024. Therapeutic antibodies for cancer and other diseases are developed. The company has 732 employees. MorphoSys has completed 4 acquisitions, including Biogenesis, Constellation Pharma and Lanthio Pharma. Its chief executive, as recorded, is Jean-Paul Kress. Its focus areas include Life Sciences, Immunotherapy, Antibody and Immunomodulatory.
Company details
Founded in 1992 and based in Planegg, Germany, MorphoSys operates as an integrated biopharma company focused on the discovery, development, and commercialization of therapeutic antibodies. Targets include cancer, Alzheimers disease, infectious diseases, cardiovascular dysfunction, and inflammation. Key technologies encompass HuCAL and Ylanthia libraries for generating human antibodies. The lead product candidate, MOR208, addresses diffuse large B-cell lymphoma.
- Headquarters Planegg, Germany
- Employees 732
- Founders Andreas Pluckthun
- Stage Acquired
- SectorsHealthcare
- Email••••••••
- Phone•••• ••••
- Website morphosys.com
- Social LinkedIn X Facebook
- Acquired by Novartis (Feb 2024)
- Net Profit-$126.36 M (USD)-48as on Dec 31, 2020
- EBITDA-$124.85 M (USD)-45as on Dec 31, 2020
- Latest Funding Round$383.84M (USD), Post-IPO
Oct 2020
- InvestorsNovartis
& 1 more
- Employee Count732
- Investments & AcquisitionsBiogenesis
& 3 more
- Acquired byNovartis
(Feb 2024)
Funding Insights of MorphoSys
- Total Rounds 4
- Last Round Post-IPO — $383.84M
- First Round $112.32M
(Sep 2013)
- Investors Count 1
All 4 funding rounds of MorphoSys with amounts and investors; the two latest post-money valuations are shown, the rest are part of the premium plan.
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Oct 2020 | $383.84M | Post-IPO | – | – | – |
| Jan 2020 | $150M | Post-IPO | – | – | |
| Nov 2016 | $123.9M | Post-IPO | – | – | – |
| Sep 2013 | $112.32M | Post-IPO | – | – | – |
2 investors in total: 2 institutional.
Investors in MorphoSys
MorphoSys has secured backing from 2 investors, including institutional investors. Prominent investors backing the company include Novartis and Incyte.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
Small molecules are developed for cancer and skin disease treatments. | 1991 | incyte.com | Wilmington, United States | |
R&D focused on manufacturing of drugs for multiple therapeutic areas | 1996 | novartis.com | Basel, Switzerland |
Investor details for MorphoSys
The complete investor list, round-by-round participation and investor portfolios require an active premium plan.
- Complete investor list
- Round participation
- Investor portfolios
- Co-investor network
Verified entity values are shown only after access is granted.
People of MorphoSys
617 people are tracked at MorphoSys (371 in leadership, 12 in board & advisors, 234 in team); the tracked headcount is 732.
| Name | Role | Group |
|---|---|---|
Andreas Pluckthun | Co-Founder | Leadership |
Jean-Paul Kress | CEO | Leadership |
Johanne Dinucci | Region Head, Customer Operations & Patient Services | Leadership |
Anne Marie Johnson | Associate Director, Business Insights & Analytics | Leadership |
Gerry Gettinger | Team Leader/sales Director Alternate Channels | Leadership |
Abhishek Srivastava | Associate Director - PSS Analytics & Effectiveness | Leadership |
Markus Gruber | Head IP Solid Tumors And AAA At Novartis | Leadership |
Anonymous | Chief Strategy & Growth Officer | Leadership |
Sherry Smith | Associate Director - People Partner | Leadership |
rheyan cader | Global Head Of People & Organization, RLT Operations | Leadership |
Bridget Stuart | Director, Translational Medicine Discovery And Profiling | Leadership |
Gwennaelle Monnot | Principal Scientist (lab Head) | Leadership |
Nancy Turner | Director | Leadership |
Jennifer Ntiri | Associate Director - NPS Process & Design Improvement | Leadership |
Karen L. Hale | Chief Legal Officer | Leadership |
Tim Sayegh | Director, Marketing Strategy - Multiple Sclerosis Portfolio | Leadership |
Victor Bulto | President, Innovative Medicines US | Leadership |
John Jameson | Business Unit Sales Director | Leadership |
Tara Conforto | Director | Leadership |
Stephanie Danetz | Director | Leadership |
597 more people are available in the full profile.
Complete people profiles for MorphoSys
Full employee and board profiles, team structure, tenure and professional contact details require an active premium plan.
- Full employee list
- Team structure
- Board tenure
- Professional contacts
Verified entity values are shown only after access is granted.
Investments & Acquisitions by MorphoSys
MorphoSys has strategically engaged in corporate development activities, having acquired 4 companies. Notable acquisitions include Biogenesis, Constellation Pharma and Lanthio Pharma.
| Company Name | Description | Domain | Location | Founded | Acquired | Amount |
|---|---|---|---|---|---|---|
Developer of drugs in the field of epigenetics | constellationpharma.com | Cambridge, United States | 2008 | Jun 2021 | $1.7B | |
Speciality company developing and commercializing therapeutic peptide drugs against difficult to target receptors | lanthiopharma.com | Groningen, Netherlands | 2010 | May 2015 | $22.51M | |
Technology for the construction of protein libraries | sloning.com | Puchheim, Germany | 2001 | Oct 2010 | $26.5M | |
Custom antibodies are developed and commercialized for research. | biogenesis.co.uk | Poole, United Kingdom | 1984 | Jan 2005 | •••• |
Complete acquisition details for MorphoSys
Acquired stakes, deal sources and the complete acquisition history require an active premium plan.
- Acquired stakes
- Deal sources
- Complete history
- Exports
Verified entity values are shown only after access is granted.
Timeline of MorphoSys
9 dated milestones of MorphoSys across 32 years, from founding to its latest funding, stage changes and deals.
- Founded MorphoSys is founded.
- Acquisition Acquires Biogenesis.
- Acquisition Acquires Sloning BioTechnology.
- Funding First funding round of $112.3M.
- Acquisition Acquires Lanthio Pharma.
- IPO Lists on the stock exchange (IPO).
- Funding Latest funding round, Post-IPO, of $383.8M.
- Acquisition Acquires Constellation Pharma.
- Exit Acquired by Novartis.
Web traffic of MorphoSys
Websites that share an audience with MorphoSys (morphosys.com).
Websites whose visitors overlap most with MorphoSys. Affinity shows how closely the audiences match.
| Website | Domain | Audience affinity | Monthly visits | Global rank | Profile |
|---|---|---|---|---|---|
precisionantibody.com | precisionantibody.com | 100% | #3,295,457 | – | |
| encorbio.com | 89% | #3,038,138 | View details | ||
biolytix.ch | biolytix.ch | 88% | #5,277,105 | – | |
biotec-fischer.de | biotec-fischer.de | 88% | – | ||
bml-laboratorien.de | bml-laboratorien.de | 88% | – | ||
| •••••••••• | ••••••.com | ••% | •.•M | #••••• | – |
| •••••••••• | ••••••.com | ••% | •.•M | #••••• | – |
| •••••••••• | ••••••.com | ••% | •.•M | #••••• | – |
All 15 similar websites and full traffic analytics for MorphoSys
The complete similar-websites list, audience overlap and engagement analytics require an active premium plan.
- 15 similar websites
- Audience overlap
- Engagement analytics
- Traffic by brand
Verified entity values are shown only after access is granted.
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Related news about Morphosys
Complete news archive for MorphoSys
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about MorphoSys
MorphoSys was founded in 1992 and raised its 1st funding round 21 years after it was founded.
MorphoSys is headquartered in Planegg, Germany. It is registered at Planegg, Bavaria, Germany.
Jean-Paul Kress is the CEO of MorphoSys, as recorded in our data.
MorphoSys has 732 employees.
Founded in 1992 and based in Planegg, Germany, MorphoSys operates as an integrated biopharma company focused on the discovery, development, and commercialization of therapeutic antibodies. Targets include cancer, Alzheimers disease, infectious diseases, cardiovascular dysfunction, and inflammation. Key technologies encompass HuCAL and Ylanthia libraries for generating human antibodies. The lead product candidate, MOR208, addresses diffuse large B-cell lymphoma.
MorphoSys has made 4 acquisitions, including Biogenesis, Constellation Pharma, and Lanthio Pharma.
Yes. MorphoSys was acquired by Novartis in February 2024.